These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32057682)

  • 41. Pathology of the endocrine pancreas.
    Heitz PU; Kasper M; Polak JM; Klöppel G
    J Histochem Cytochem; 1979 Oct; 27(10):1401-2. PubMed ID: 229158
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sirtuin-1 regulates acinar-to-ductal metaplasia and supports cancer cell viability in pancreatic cancer.
    Wauters E; Sanchez-Arévalo Lobo VJ; Pinho AV; Mawson A; Herranz D; Wu J; Cowley MJ; Colvin EK; Njicop EN; Sutherland RL; Liu T; Serrano M; Bouwens L; Real FX; Biankin AV; Rooman I
    Cancer Res; 2013 Apr; 73(7):2357-67. PubMed ID: 23370328
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fibroblast subtypes in pancreatic cancer and pancreatitis: from mechanisms to therapeutic strategies.
    Huang H; Lu W; Zhang X; Pan J; Cao F; Wen L
    Cell Oncol (Dordr); 2024 Apr; 47(2):383-396. PubMed ID: 37721678
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues.
    Dal Molin M; Kim H; Blackford A; Sharma R; Goggins M
    Pancreas; 2016 Apr; 45(4):613-9. PubMed ID: 26495786
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pancreatic carcinoma with duct, endocrine, and acinar differentiation. A histologic, immunocytochemical, and ultrastructural study.
    Schron DS; Mendelsohn G
    Cancer; 1984 Nov; 54(9):1766-70. PubMed ID: 6089999
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Response assessment in pancreatic ductal adenocarcinoma: role of imaging.
    Baliyan V; Kordbacheh H; Parakh A; Kambadakone A
    Abdom Radiol (NY); 2018 Feb; 43(2):435-444. PubMed ID: 29243123
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mixed exocrine-endocrine tumors of the pancreas.
    Klöppel G
    Semin Diagn Pathol; 2000 May; 17(2):104-8. PubMed ID: 10839610
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New Diagnostic and Therapeutic Aspects of Pancreatic Ductal Adenocarcinoma.
    Mangge H; Niedrist T; Renner W; Lyer S; Alexiou C; Haybaeck J
    Curr Med Chem; 2017; 24(28):3012-3024. PubMed ID: 28494747
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.
    Yeh R; Dercle L; Garg I; Wang ZJ; Hough DM; Goenka AH
    Abdom Radiol (NY); 2018 Feb; 43(2):415-434. PubMed ID: 29143875
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma.
    Zhu J; Wu J; Pei X; Tan Z; Shi J; Lubman DM
    PLoS One; 2017; 12(4):e0175039. PubMed ID: 28369074
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma.
    Hu X; Xia F; Lee J; Li F; Lu X; Zhuo X; Nie G; Ling D
    Adv Sci (Weinh); 2021 Apr; 8(7):2002545. PubMed ID: 33854877
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hes1 Controls Exocrine Cell Plasticity and Restricts Development of Pancreatic Ductal Adenocarcinoma in a Mouse Model.
    Hidalgo-Sastre A; Brodylo RL; Lubeseder-Martellato C; Sipos B; Steiger K; Lee M; von Figura G; Grünwald B; Zhong S; Trajkovic-Arsic M; Neff F; Schmid RM; Siveke JT
    Am J Pathol; 2016 Nov; 186(11):2934-2944. PubMed ID: 27639167
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunocytochemistry of normal pancreatic islets and spontaneous islet cell tumors in dogs.
    Hawkins KL; Summers BA; Kuhajda FP; Smith CA
    Vet Pathol; 1987 Mar; 24(2):170-9. PubMed ID: 2883753
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
    Zhao L; Zhao H; Yan H
    BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions.
    Tan E; El-Rayes B
    J Gastrointest Cancer; 2019 Mar; 50(1):1-8. PubMed ID: 30446922
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
    Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
    Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neo-adjuvant therapy for pancreatic cancer: hope for the future.
    Borazanci E; Sckolnik S; Amini A
    Expert Rev Gastroenterol Hepatol; 2019 Jun; 13(6):579-589. PubMed ID: 30979348
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Desmoplasia and oncogene driven acinar-to-ductal metaplasia are concurrent events during acinar cell-derived pancreatic cancer initiation in young adult mice.
    Johnson BL; d'Alincourt Salazar M; Mackenzie-Dyck S; D'Apuzzo M; Shih HP; Manuel ER; Diamond DJ
    PLoS One; 2019; 14(9):e0221810. PubMed ID: 31490946
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Functional pathology of pancreatic islets: immunocytochemical exploration.
    Mukai K
    Pathol Annu; 1983; 18 Pt 2():87-107. PubMed ID: 6326027
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma.
    Tsai S; Christians KK; George B; Ritch PS; Dua K; Khan A; Mackinnon AC; Tolat P; Ahmad SA; Hall WA; Erickson BA; Evans DB
    Ann Surg; 2018 Oct; 268(4):610-619. PubMed ID: 30080723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.